What You Need To Know About Liability Protection For COVID-19 Products
Companies developing medical countermeasures for COVID-19 need to become familiar with divergences in the liability protection offered by different countries with regard to possible safety issues that may arise when products are fast-tracked for public health reasons. By doing so they can adopt a systematic process for prospectively evaluating and managing international risks, say Dan Kracov, Lincoln Tsang and Alexander Roussanov.
You may also be interested in...
As the race to develop COVID-19 vaccines continues, EU member states are ready to financially cover certain of the companies’ risks, but not to change the rules on liability. Transparency proponents are calling for all contracts on vaccine purchases to be made public.
The two first-ever therapies to offer sickle cell disease patients the possibility of lifetime relief from painful vaso-occlusive events or crises are hitting the market, but face tough commercial challenges.
Medicaid is expected to be the primary payer for the sickle cell treatments. Bluebird bio maintains an outcomes-based arrangement is a key part of its access strategy and will overcome what appears to be a significant competitive disadvantage on price compared to the Vertex product.